Opaleye Management
Latest statistics and disclosures from Opaleye Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LQDA, ETON, HROW, IRON, URGN, and represent 46.74% of Opaleye Management's stock portfolio.
- Added to shares of these 10 stocks: IRON (+$32M), IMMX (+$24M), MGTX (+$19M), GLUE (+$18M), REPL (+$15M), CABA (+$7.7M), VSTM (+$6.9M), EDIT (+$6.3M), BBOT, LYEL.
- Started 13 new stock positions in PTN, IMMX, GLUE, PHAT, ADCT, REPL, OKYO, VSTM, Hemab Therapeutics Holdings, BHVN. INBX, TRAX, KTTA.
- Reduced shares in these 10 stocks: CATX (-$20M), HROW (-$18M), LQDA (-$7.8M), SNWV (-$6.8M), JBIO (-$6.3M), CGON (-$5.5M), Assertio Holdings (-$5.1M), STRO, DERM, QTTB.
- Sold out of its positions in Assertio Holdings, CATX, Perspective Therapeutics, LBRX, NXTC, PLX, RIGL, STRO, TECX.
- Opaleye Management was a net buyer of stock by $59M.
- Opaleye Management has $1.1B in assets under management (AUM), dropping by 45.44%.
- Central Index Key (CIK): 0001595855
Tip: Access up to 7 years of quarterly data
Positions held by Opaleye Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Opaleye Management
Opaleye Management holds 58 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Liquidia Corporation Com New (LQDA) | 17.7 | $195M | -3% | 2.4M | 79.73 |
|
| Eton Pharmaceuticals (ETON) | 9.4 | $104M | 2.9M | 36.20 |
|
|
| Harrow Health (HROW) | 9.2 | $102M | -15% | 2.4M | 42.47 |
|
| Disc Medicine (IRON) | 5.7 | $63M | +103% | 855k | 73.14 |
|
| Urogen Pharma (URGN) | 4.8 | $53M | 1.4M | 36.80 |
|
|
| Apogee Therapeutics (APGE) | 4.7 | $52M | 390k | 132.73 |
|
|
| Meiragtx Holdings (MGTX) | 4.3 | $48M | +67% | 3.6M | 13.51 |
|
| Sol-gel Technologies Shs New (SLGL) | 3.4 | $37M | 500k | 74.14 |
|
|
| Rezolute Com New (RZLT) | 3.0 | $33M | 6.3M | 5.20 |
|
|
| Tg Therapeutics (TGTX) | 2.7 | $29M | 535k | 54.94 |
|
|
| Immix Biopharma (IMMX) | 2.2 | $24M | NEW | 2.3M | 10.31 |
|
| Crescent Biopharma (CBIO) | 2.2 | $24M | 1.3M | 18.00 |
|
|
| Stoke Therapeutics (STOK) | 2.1 | $23M | 700k | 32.72 |
|
|
| Alpha Cognition Com New (ACOG) | 1.9 | $21M | +13% | 2.9M | 7.22 |
|
| Edgewise Therapeutics (EWTX) | 1.8 | $20M | 500k | 40.63 |
|
|
| Revolution Medicines (RVMD) | 1.7 | $19M | 100k | 187.28 |
|
|
| Monte Rosa Therapeutics (GLUE) | 1.6 | $18M | NEW | 745k | 24.20 |
|
| Alumis (ALMS) | 1.4 | $16M | 550k | 28.14 |
|
|
| Codexis (CDXS) | 1.4 | $15M | 6.8M | 2.26 |
|
|
| Replimune Group (REPL) | 1.4 | $15M | NEW | 1.4M | 11.07 |
|
| Xoma Royalty Corporation Com New (XOMA) | 1.3 | $14M | +12% | 338k | 42.50 |
|
| Mbx Biosciences (MBX) | 1.3 | $14M | 260k | 55.20 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 1.2 | $14M | 123k | 111.03 |
|
|
| Editas Medicine (EDIT) | 1.1 | $13M | +100% | 3.9M | 3.24 |
|
| Protagonist Therapeutics (PTGX) | 1.1 | $12M | 100k | 122.58 |
|
|
| Cabaletta Bio (CABA) | 1.1 | $12M | +179% | 3.9M | 3.11 |
|
| Q32 Bio (QTTB) | 1.1 | $12M | -25% | 931k | 12.74 |
|
| Annexon (ANNX) | 0.9 | $9.8M | -26% | 1.7M | 5.71 |
|
| Verastem Com New (VSTM) | 0.6 | $6.9M | NEW | 1.8M | 3.82 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.6 | $6.9M | 1.4M | 4.85 |
|
|
| Relmada Therapeutics (RLMD) | 0.6 | $6.5M | 935k | 6.92 |
|
|
| Ocular Therapeutix (OCUL) | 0.5 | $5.9M | 600k | 9.82 |
|
|
| Trevi Therapeutics (TRVI) | 0.5 | $5.8M | -10% | 310k | 18.65 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.5 | $5.3M | +1213% | 700k | 7.62 |
|
| Lyell Immunopharma Com New (LYEL) | 0.4 | $4.8M | +334% | 344k | 14.05 |
|
| Ocuphire Pharma (IRD) | 0.4 | $4.6M | 1.1M | 4.11 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 0.4 | $4.4M | +197% | 334k | 13.30 |
|
| Intellia Therapeutics (NTLA) | 0.4 | $4.2M | +2% | 250k | 16.92 |
|
| Voyager Therapeutics (VYGR) | 0.4 | $4.1M | +3% | 1.2M | 3.50 |
|
| Biodesix (BDSX) | 0.4 | $4.1M | -24% | 180k | 22.55 |
|
| Rocket Pharmaceuticals (RCKT) | 0.3 | $3.4M | +4% | 1.0M | 3.42 |
|
| Jade Biosciences Com New (JBIO) | 0.3 | $3.2M | -66% | 145k | 22.22 |
|
| Sanuwave Health (SNWV) | 0.3 | $3.1M | -68% | 306k | 10.00 |
|
| Fortress Biotech Com New (FBIO) | 0.2 | $2.7M | -14% | 890k | 3.06 |
|
| Journey Med Corp (DERM) | 0.2 | $2.5M | -63% | 350k | 7.08 |
|
| Phathom Pharmaceuticals (PHAT) | 0.2 | $2.0M | NEW | 186k | 10.85 |
|
| Inhibrx Biosciences (INBX) | 0.2 | $1.9M | NEW | 20k | 94.75 |
|
| Enanta Pharmaceuticals (ENTA) | 0.2 | $1.8M | 125k | 14.58 |
|
|
| Hemab Therapeutics Hldgs Com Shs | 0.2 | $1.8M | NEW | 48k | 36.73 |
|
| First Tracks Biotherapeutics Ord Shs (TRAX) | 0.1 | $1.3M | NEW | 65k | 20.12 |
|
| Cg Oncology (CGON) | 0.1 | $1.3M | -81% | 18k | 71.05 |
|
| Biohaven (BHVN) | 0.1 | $1.2M | NEW | 78k | 14.88 |
|
| Atea Pharmaceuticals (AVIR) | 0.1 | $1.1M | -27% | 235k | 4.65 |
|
| Pasithea Therapeutics Corp Com New (KTTA) | 0.1 | $1.1M | NEW | 2.1M | 0.52 |
|
| Adc Therapeutics Sa SHS (ADCT) | 0.1 | $749k | NEW | 700k | 1.07 |
|
| Okyo Pharma Shs New (OKYO) | 0.1 | $563k | NEW | 375k | 1.50 |
|
| Palatin Technologies Com New (PTN) | 0.0 | $221k | NEW | 21k | 10.79 |
|
| Adagio Med Hldgs (ADGM) | 0.0 | $13k | 18k | 0.72 |
|
Past Filings by Opaleye Management
SEC 13F filings are viewable for Opaleye Management going back to 2013
- Opaleye Management 2026 Q2 filed Aug. 14, 2026
- Opaleye Management 2026 Q1 filed May 15, 2026
- Opaleye Management 2025 Q4 restated filed April 13, 2026
- Opaleye Management 2025 Q4 filed Feb. 17, 2026
- Opaleye Management 2025 Q3 filed Nov. 14, 2025
- Opaleye Management 2025 Q2 restated filed Aug. 15, 2025
- Opaleye Management 2025 Q1 filed May 15, 2025
- Opaleye Management 2024 Q4 filed Feb. 14, 2025
- Opaleye Management 2024 Q3 filed Nov. 14, 2024
- Opaleye Management 2024 Q2 filed Aug. 14, 2024
- Opaleye Management 2024 Q1 restated filed May 29, 2024
- Opaleye Management 2024 Q1 filed May 15, 2024
- Opaleye Management 2023 Q4 filed Feb. 14, 2024
- Opaleye Management 2023 Q3 filed Nov. 15, 2023
- Opaleye Management 2023 Q2 filed Aug. 14, 2023
- Opaleye Management 2023 Q1 filed May 15, 2023